The University of Queensland and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and has a strong safety profile. There were no serious adverse events or safety concerns reported in the 216 trial participants. However, following consultation with the Australian Government, CSL will not progress the vaccine candidate to Phase 2/3 clinical trials.
Update on UQ COVID-19 vaccine
11 Dec 2020
Latest
-
-
Revealing what makes bacteria life-threatening
22 February 2024 -
Trapping sulfate to benefit health, industry and waterways
15 February 2024